Brief: Basilea Pharmaceutica - Strong Cresemba Sales In Europe Trigger USD 37.5 Mln Milestone Payment
Tue 06:16
BRIEF-Basilea Pharmaceutica - Strong Cresemba Sales In Europe Trigger USD 37.5 Mln Milestone Payment Nov 3 (Reuters) - BASILEA PHARMACEUTICA AGBSLN.S:
STRONG CRESEMBA (ISAVUCONAZOLE) SALES IN EUROPE TRIGGER USD 37.5 MILLION MILESTONE PAYMENT TO BASILEA
Source text: ID:nGNX3F1h9v
Further company coverage: BSLN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Basilea Pharmaceutica AG, Allschwil
See all newsBrief: Basilea Pharmaceutica - Strong Cresemba Sales In Europe Trigger USD 37.5 Mln Milestone Payment
Basilea seen up after raising 2026 guidance
Brief: Basilea Expects 2026 Operating Profit Of CHF 115 Mln
Brief: Basilea Reports Presentation Of New Data For Fosmanogepix, Isavuconazole And Ceftobiprole At IDWeek 2026
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments